Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-10-17

AUTHORS

F. Nolte, B. Höchsmann, A. Giagounidis, M. Lübbert, U. Platzbecker, D. Haase, A. Lück, N. Gattermann, M. Taupitz, M. Baier, O. Leismann, A. Junkes, C. Schumann, W. K. Hofmann, H. Schrezenmeier

ABSTRACT

The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in MDS is rather limited. Here we present the results of a multi-center trial evaluating the efficacy and safety of deferasirox (DFX) in low and intermediate-1 risk MDS patients with transfusion-dependent IOL. Three patients with transfusion frequency of > 4 units PRBC per month were initially treated with 30 mg/kg/day while in 46 patients with a lower transfusion burden deferasirox was initiated at 20 mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6 mg/kg/day only. LIC was measured by MRI at baseline and end of study using the method by St. Pierre et al. The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69 years who were treated with DFX for a median duration of 354 days. Mean daily dose of DFX was 19 mg/kg/day. Median serum ferritin level (SF) at baseline was 2,447 ng/mL and decreased to 1,685 ng/mL (reduction by 31 %) at end of study (p = 0.01). In 7 (13 %) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy. For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8 mg/g dry tissue weight (± 8.3 mg/g dry tissue weight) at study entry to 10,8 mg/g dry tissue weight (± 10.4 mg/g dry tissue weight) at end of study (p = 0.01). Of all patients exposed to the study drug (n = 54), 28 (52 %) did not complete the 12 month study period most commonly due to AEs in 28 % (n = 15) and abnormal laboratory values in 7 % (n = 4), respectively. The most common adverse events (≥ 10 % of all patients) with suspected drug relationship were diarrhea (n = 25, 46 %), nausea (n = 13, 24 %), upper abdominal pain (n = 8, 15 %), serum creatinine increase (n = 16, 30 %) and rash (n = 5, 9 %). Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61 %). Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11 %). Initiation of treatment of IOL with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. The safety profile of DFX was comparable to previous observations. More... »

PAGES

191-198

Journal

TITLE

Annals of Hematology

ISSUE

2

VOLUME

92

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z

DOI

http://dx.doi.org/10.1007/s00277-012-1594-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017282293

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23073603


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chelation Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Creatinine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deferasirox", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Eruptions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ferritins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron Chelating Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron Overload", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transfusion Reaction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411778.c", 
          "name": [
            "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nolte", 
        "givenName": "F.", 
        "id": "sg:person.0603675126.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603675126.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-W\u00fcrttemberg\u2014Hessen und Universit\u00e4t Ulm, Ulm, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6582.9", 
          "name": [
            "Institut f\u00fcr klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-W\u00fcrttemberg\u2014Hessen und Universit\u00e4t Ulm, Ulm, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "H\u00f6chsmann", 
        "givenName": "B.", 
        "id": "sg:person.01354105066.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354105066.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medizinische Klinik II, H\u00e4matologie und Onkologie, St. Johannes Hospital, Duisburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.459950.4", 
          "name": [
            "Medizinische Klinik II, H\u00e4matologie und Onkologie, St. Johannes Hospital, Duisburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giagounidis", 
        "givenName": "A.", 
        "id": "sg:person.01164215515.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164215515.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abteilung f\u00fcr Innere Medizin I, H\u00e4matologie und Onkologie, Universit\u00e4tsklinikum Freiburg, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Abteilung f\u00fcr Innere Medizin I, H\u00e4matologie und Onkologie, Universit\u00e4tsklinikum Freiburg, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00fcbbert", 
        "givenName": "M.", 
        "id": "sg:person.01153663723.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Germany", 
          "id": "http://www.grid.ac/institutes/grid.412282.f", 
          "name": [
            "Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Platzbecker", 
        "givenName": "U.", 
        "id": "sg:person.0670313557.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670313557.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abteilung f\u00fcr H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411984.1", 
          "name": [
            "Abteilung f\u00fcr H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haase", 
        "givenName": "D.", 
        "id": "sg:person.0754465332.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754465332.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Onkologisch-urologische Praxis, Rostock, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Onkologisch-urologische Praxis, Rostock, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00fcck", 
        "givenName": "A.", 
        "id": "sg:person.01011222414.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011222414.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abteilung f\u00fcr H\u00e4matologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Abteilung f\u00fcr H\u00e4matologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gattermann", 
        "givenName": "N.", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr Radiologie und Klinik f\u00fcr Strahlenheilkunde, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Institut f\u00fcr Radiologie und Klinik f\u00fcr Strahlenheilkunde, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Taupitz", 
        "givenName": "M.", 
        "id": "sg:person.01116413157.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116413157.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma GmbH, N\u00fcrnberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, N\u00fcrnberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baier", 
        "givenName": "M.", 
        "id": "sg:person.0637560050.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637560050.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma GmbH, N\u00fcrnberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, N\u00fcrnberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leismann", 
        "givenName": "O.", 
        "id": "sg:person.0770220465.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770220465.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma GmbH, N\u00fcrnberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, N\u00fcrnberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Junkes", 
        "givenName": "A.", 
        "id": "sg:person.0653772065.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653772065.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411778.c", 
          "name": [
            "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schumann", 
        "givenName": "C.", 
        "id": "sg:person.01037616506.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037616506.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411778.c", 
          "name": [
            "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hofmann", 
        "givenName": "W. K.", 
        "id": "sg:person.0710371040.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710371040.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-W\u00fcrttemberg\u2014Hessen und Universit\u00e4t Ulm, Ulm, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6582.9", 
          "name": [
            "Institut f\u00fcr klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-W\u00fcrttemberg\u2014Hessen und Universit\u00e4t Ulm, Ulm, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schrezenmeier", 
        "givenName": "H.", 
        "id": "sg:person.01236224761.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236224761.06"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s002280000251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050991082", 
          "https://doi.org/10.1007/s002280000251"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-010-1091-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003969238", 
          "https://doi.org/10.1007/s00277-010-1091-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-012-1481-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043187265", 
          "https://doi.org/10.1007/s00277-012-1481-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-10-17", 
    "datePublishedReg": "2012-10-17", 
    "description": "The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in MDS is rather limited. Here we present the results of a multi-center trial evaluating the efficacy and safety of deferasirox (DFX) in low and intermediate-1 risk MDS patients with transfusion-dependent IOL. Three patients with transfusion frequency of >\u20094 units PRBC per month were initially treated with 30\u00a0mg/kg/day while in 46 patients with a lower transfusion burden deferasirox was initiated at 20\u00a0mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6\u00a0mg/kg/day only. LIC was measured by MRI at baseline and end of study using the method by St. Pierre et al. The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69\u00a0years who were treated with DFX for a median duration of 354\u00a0days. Mean daily dose of DFX was 19\u00a0mg/kg/day. Median serum ferritin level (SF) at baseline was 2,447\u00a0ng/mL and decreased to 1,685\u00a0ng/mL (reduction by 31\u00a0%) at end of study (p\u2009=\u20090.01). In 7 (13\u00a0%) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy. For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8\u00a0mg/g dry tissue weight (\u00b1 8.3\u00a0mg/g dry tissue weight) at study entry to 10,8\u00a0mg/g dry tissue weight (\u00b1 10.4\u00a0mg/g dry tissue weight) at end of study (p\u2009=\u20090.01). Of all patients exposed to the study drug (n\u2009=\u200954), 28 (52\u00a0%) did not complete the 12\u00a0month study period most commonly due to AEs in 28\u00a0% (n\u2009=\u200915) and abnormal laboratory values in 7\u00a0% (n\u2009=\u20094), respectively. The most common adverse events (\u2265\u200910\u00a0% of all patients) with suspected drug relationship were diarrhea (n\u2009=\u200925, 46\u00a0%), nausea (n\u2009=\u200913, 24\u00a0%), upper abdominal pain (n\u2009=\u20098, 15\u00a0%), serum creatinine increase (n\u2009=\u200916, 30\u00a0%) and rash (n\u2009=\u20095, 9\u00a0%). Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61\u00a0%). Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11\u00a0%). Initiation of treatment of IOL with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. The safety profile of DFX was comparable to previous observations.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-012-1594-z", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "92"
      }
    ], 
    "keywords": [
      "packed red blood cells", 
      "liver iron concentration", 
      "end of study", 
      "serum ferritin levels", 
      "transfusion-dependent iron overload", 
      "myelodysplastic syndrome", 
      "multi-center trial", 
      "iron overload", 
      "study drug", 
      "adverse events", 
      "ferritin levels", 
      "int-1 risk myelodysplastic syndrome", 
      "tissue weight", 
      "liver MRI", 
      "median serum ferritin levels", 
      "units Packed Red Blood Cells", 
      "total body iron content", 
      "safety of deferasirox", 
      "risk MDS patients", 
      "upper abdominal pain", 
      "serum creatinine increase", 
      "common adverse events", 
      "risk myelodysplastic syndromes", 
      "majority of patients", 
      "abnormal laboratory values", 
      "initiation of treatment", 
      "liver iron content", 
      "body iron content", 
      "month study period", 
      "transfusion frequency", 
      "oral deferasirox", 
      "abdominal pain", 
      "creatinine increase", 
      "hematologic improvement", 
      "red blood cells", 
      "median duration", 
      "regular transfusions", 
      "median age", 
      "daily dose", 
      "study entry", 
      "dose adjustment", 
      "MDS patients", 
      "MDS patients", 
      "safety profile", 
      "IWG criteria", 
      "one patient", 
      "laboratory values", 
      "chelation therapy", 
      "unsatisfactory efficacy", 
      "patients", 
      "deferasirox", 
      "dry tissue weight", 
      "single arm", 
      "blood cells", 
      "study period", 
      "MRI", 
      "LIC measurements", 
      "dose", 
      "baseline", 
      "efficacy", 
      "drug relationship", 
      "syndrome", 
      "excess iron", 
      "trials", 
      "days", 
      "drugs", 
      "overload", 
      "safety", 
      "nausea", 
      "transfusion", 
      "rash", 
      "pain", 
      "diarrhea", 
      "anemia", 
      "previous observations", 
      "therapy", 
      "study", 
      "iron concentration", 
      "months", 
      "age", 
      "iron content", 
      "levels", 
      "treatment", 
      "risk", 
      "weight", 
      "sufficient reduction", 
      "duration", 
      "events", 
      "cells", 
      "arm", 
      "majority", 
      "population", 
      "initiation", 
      "years", 
      "interruption", 
      "end", 
      "adjustment", 
      "period", 
      "criteria", 
      "increase", 
      "entry", 
      "reduction", 
      "improvement", 
      "profile", 
      "concentration", 
      "results", 
      "frequency", 
      "data", 
      "relationship", 
      "detection", 
      "intention", 
      "measurements", 
      "content", 
      "tool", 
      "values", 
      "observations", 
      "iron", 
      "method", 
      "et al", 
      "AES", 
      "al"
    ], 
    "name": "Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload", 
    "pagination": "191-198", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017282293"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-012-1594-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23073603"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-012-1594-z", 
      "https://app.dimensions.ai/details/publication/pub.1017282293"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_557.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-012-1594-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z'


 

This table displays all metadata directly associated to this object as RDF triples.

418 TRIPLES      21 PREDICATES      173 URIs      162 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-012-1594-z schema:about N0faf950b18b3426eb2756b6bcb1444e5
2 N10b14962443d4b83a47b1a589ff7a08a
3 N1b3bd0bb7a6145358f148a62ab0a2287
4 N203849cc279a4c01b8e6d4d690ed0258
5 N3517fde2d3c0420798438d6196f938ae
6 N437c1e6a200c41ff8745cc077c2aa4f1
7 N50e9fea6fdea4c979b85d2df48bc1059
8 N587b8b006bf746f6816374c4db8def5c
9 N5a37a64200624ec093ea8e00710fd2d9
10 N5d191a597ad24dd0b3cf015eebaf1368
11 N66780ddaa2724d7ea4e613433d431623
12 N77c90dcb23704fb2932191a8ab6e0abd
13 N787b810a887b41e780ff7ae11fa624ca
14 N8f83f33c7c0c411cace2fb4d2422f0f9
15 N9f81a964d62345dbb9d4f59702d0ba49
16 Naafda2a92a78402083ad4d014c38ec4d
17 Naf153af92cbd4e0689f09dfa89ba72a0
18 Nc6483fc71e184afe955f2f3a0debf844
19 Nc8a9c5dbde834ddc8c7b26186dcb36a1
20 Ncd6909f1eb5d4e90b1b3e61d468dba78
21 Nd2af1c72fe384d928b7b671469eb4466
22 Nd4b9a438194f482e832d977c78f8716a
23 Ne7fd4c94f18c47fc888606d35e94d897
24 Nf05c77eda2a74ce18df1cad3c98e93d7
25 Nfabbc922cb0f45e880fddc47591d9c50
26 anzsrc-for:11
27 anzsrc-for:1103
28 schema:author Nbb1a1a34aaf94726be5bb000c893df65
29 schema:citation sg:pub.10.1007/s002280000251
30 sg:pub.10.1007/s00277-010-1091-1
31 sg:pub.10.1007/s00277-012-1481-7
32 schema:datePublished 2012-10-17
33 schema:datePublishedReg 2012-10-17
34 schema:description The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in MDS is rather limited. Here we present the results of a multi-center trial evaluating the efficacy and safety of deferasirox (DFX) in low and intermediate-1 risk MDS patients with transfusion-dependent IOL. Three patients with transfusion frequency of > 4 units PRBC per month were initially treated with 30 mg/kg/day while in 46 patients with a lower transfusion burden deferasirox was initiated at 20 mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6 mg/kg/day only. LIC was measured by MRI at baseline and end of study using the method by St. Pierre et al. The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69 years who were treated with DFX for a median duration of 354 days. Mean daily dose of DFX was 19 mg/kg/day. Median serum ferritin level (SF) at baseline was 2,447 ng/mL and decreased to 1,685 ng/mL (reduction by 31 %) at end of study (p = 0.01). In 7 (13 %) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy. For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8 mg/g dry tissue weight (± 8.3 mg/g dry tissue weight) at study entry to 10,8 mg/g dry tissue weight (± 10.4 mg/g dry tissue weight) at end of study (p = 0.01). Of all patients exposed to the study drug (n = 54), 28 (52 %) did not complete the 12 month study period most commonly due to AEs in 28 % (n = 15) and abnormal laboratory values in 7 % (n = 4), respectively. The most common adverse events (≥ 10 % of all patients) with suspected drug relationship were diarrhea (n = 25, 46 %), nausea (n = 13, 24 %), upper abdominal pain (n = 8, 15 %), serum creatinine increase (n = 16, 30 %) and rash (n = 5, 9 %). Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61 %). Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11 %). Initiation of treatment of IOL with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. The safety profile of DFX was comparable to previous observations.
35 schema:genre article
36 schema:isAccessibleForFree false
37 schema:isPartOf Na1ec53d5cbca48b88f00c05aa0d6acb8
38 Na80432e5a1c7414f8cf0af0fafe12b39
39 sg:journal.1358129
40 schema:keywords AES
41 IWG criteria
42 LIC measurements
43 MDS patients
44 MRI
45 abdominal pain
46 abnormal laboratory values
47 adjustment
48 adverse events
49 age
50 al
51 anemia
52 arm
53 baseline
54 blood cells
55 body iron content
56 cells
57 chelation therapy
58 common adverse events
59 concentration
60 content
61 creatinine increase
62 criteria
63 daily dose
64 data
65 days
66 deferasirox
67 detection
68 diarrhea
69 dose
70 dose adjustment
71 drug relationship
72 drugs
73 dry tissue weight
74 duration
75 efficacy
76 end
77 end of study
78 entry
79 et al
80 events
81 excess iron
82 ferritin levels
83 frequency
84 hematologic improvement
85 improvement
86 increase
87 initiation
88 initiation of treatment
89 int-1 risk myelodysplastic syndrome
90 intention
91 interruption
92 iron
93 iron concentration
94 iron content
95 iron overload
96 laboratory values
97 levels
98 liver MRI
99 liver iron concentration
100 liver iron content
101 majority
102 majority of patients
103 measurements
104 median age
105 median duration
106 median serum ferritin levels
107 method
108 month study period
109 months
110 multi-center trial
111 myelodysplastic syndrome
112 nausea
113 observations
114 one patient
115 oral deferasirox
116 overload
117 packed red blood cells
118 pain
119 patients
120 period
121 population
122 previous observations
123 profile
124 rash
125 red blood cells
126 reduction
127 regular transfusions
128 relationship
129 results
130 risk
131 risk MDS patients
132 risk myelodysplastic syndromes
133 safety
134 safety of deferasirox
135 safety profile
136 serum creatinine increase
137 serum ferritin levels
138 single arm
139 study
140 study drug
141 study entry
142 study period
143 sufficient reduction
144 syndrome
145 therapy
146 tissue weight
147 tool
148 total body iron content
149 transfusion
150 transfusion frequency
151 transfusion-dependent iron overload
152 treatment
153 trials
154 units Packed Red Blood Cells
155 unsatisfactory efficacy
156 upper abdominal pain
157 values
158 weight
159 years
160 schema:name Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload
161 schema:pagination 191-198
162 schema:productId N5983534ad6744d0c8d6303155635cc08
163 N9ba4923388954079b8bd72ce8df147d1
164 Na0eb87b85759450e8d397f391b9e447f
165 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017282293
166 https://doi.org/10.1007/s00277-012-1594-z
167 schema:sdDatePublished 2022-08-04T17:00
168 schema:sdLicense https://scigraph.springernature.com/explorer/license/
169 schema:sdPublisher N187b846bc7b14e818c18bd2f70201c81
170 schema:url https://doi.org/10.1007/s00277-012-1594-z
171 sgo:license sg:explorer/license/
172 sgo:sdDataset articles
173 rdf:type schema:ScholarlyArticle
174 N0e6c65393d144ff9a6eba66cd19698fd rdf:first sg:person.0670313557.25
175 rdf:rest Nb965e934f20e4a8fb45ec527b9cec11b
176 N0faf950b18b3426eb2756b6bcb1444e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Adult
178 rdf:type schema:DefinedTerm
179 N10b14962443d4b83a47b1a589ff7a08a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Ferritins
181 rdf:type schema:DefinedTerm
182 N187b846bc7b14e818c18bd2f70201c81 schema:name Springer Nature - SN SciGraph project
183 rdf:type schema:Organization
184 N1b3bd0bb7a6145358f148a62ab0a2287 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Iron Overload
186 rdf:type schema:DefinedTerm
187 N203849cc279a4c01b8e6d4d690ed0258 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Iron Chelating Agents
189 rdf:type schema:DefinedTerm
190 N257c29af79d5414f8cc4f1b0e3345314 rdf:first sg:person.0653772065.10
191 rdf:rest Nd0ea595630be49e7b3836351d56319a8
192 N3517fde2d3c0420798438d6196f938ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Male
194 rdf:type schema:DefinedTerm
195 N437c1e6a200c41ff8745cc077c2aa4f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Treatment Outcome
197 rdf:type schema:DefinedTerm
198 N43bcc75b48b141e2ae0799610727b0c6 rdf:first sg:person.0710371040.30
199 rdf:rest Nb9f679584c0448bdbf17551c1fd38925
200 N50d5831f18634973ab1c7eb9acc67b5a rdf:first sg:person.0770220465.02
201 rdf:rest N257c29af79d5414f8cc4f1b0e3345314
202 N50e9fea6fdea4c979b85d2df48bc1059 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Aged
204 rdf:type schema:DefinedTerm
205 N520ea08811bb454d99ff381c7db3399f rdf:first sg:person.0637560050.50
206 rdf:rest N50d5831f18634973ab1c7eb9acc67b5a
207 N587b8b006bf746f6816374c4db8def5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Female
209 rdf:type schema:DefinedTerm
210 N5983534ad6744d0c8d6303155635cc08 schema:name dimensions_id
211 schema:value pub.1017282293
212 rdf:type schema:PropertyValue
213 N5a37a64200624ec093ea8e00710fd2d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Gastrointestinal Diseases
215 rdf:type schema:DefinedTerm
216 N5d191a597ad24dd0b3cf015eebaf1368 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Triazoles
218 rdf:type schema:DefinedTerm
219 N66780ddaa2724d7ea4e613433d431623 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Administration, Oral
221 rdf:type schema:DefinedTerm
222 N68323cdc5e39466bbb6acda240d4740c rdf:first sg:person.01116413157.95
223 rdf:rest N520ea08811bb454d99ff381c7db3399f
224 N726331ddbeed49b48ba8bc232126bba9 rdf:first sg:person.01011222414.69
225 rdf:rest Nd34461914c9b454eaaf6ae3b4507673c
226 N77c90dcb23704fb2932191a8ab6e0abd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
227 schema:name Liver
228 rdf:type schema:DefinedTerm
229 N787b810a887b41e780ff7ae11fa624ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name Magnetic Resonance Imaging
231 rdf:type schema:DefinedTerm
232 N8f83f33c7c0c411cace2fb4d2422f0f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
233 schema:name Myelodysplastic Syndromes
234 rdf:type schema:DefinedTerm
235 N9ba4923388954079b8bd72ce8df147d1 schema:name doi
236 schema:value 10.1007/s00277-012-1594-z
237 rdf:type schema:PropertyValue
238 N9f81a964d62345dbb9d4f59702d0ba49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
239 schema:name Drug Eruptions
240 rdf:type schema:DefinedTerm
241 Na0eb87b85759450e8d397f391b9e447f schema:name pubmed_id
242 schema:value 23073603
243 rdf:type schema:PropertyValue
244 Na1ec53d5cbca48b88f00c05aa0d6acb8 schema:volumeNumber 92
245 rdf:type schema:PublicationVolume
246 Na80432e5a1c7414f8cf0af0fafe12b39 schema:issueNumber 2
247 rdf:type schema:PublicationIssue
248 Naafda2a92a78402083ad4d014c38ec4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
249 schema:name Humans
250 rdf:type schema:DefinedTerm
251 Nadc5895fe9a6444eb1cd0ece6432ccdb rdf:first sg:person.01354105066.45
252 rdf:rest Nb9faf15788564e18b15e17b467343146
253 Naf153af92cbd4e0689f09dfa89ba72a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
254 schema:name Transfusion Reaction
255 rdf:type schema:DefinedTerm
256 Nb965e934f20e4a8fb45ec527b9cec11b rdf:first sg:person.0754465332.53
257 rdf:rest N726331ddbeed49b48ba8bc232126bba9
258 Nb9f679584c0448bdbf17551c1fd38925 rdf:first sg:person.01236224761.06
259 rdf:rest rdf:nil
260 Nb9faf15788564e18b15e17b467343146 rdf:first sg:person.01164215515.10
261 rdf:rest Nc3a8de01b7834f809284490cf9ac48dc
262 Nbb1a1a34aaf94726be5bb000c893df65 rdf:first sg:person.0603675126.07
263 rdf:rest Nadc5895fe9a6444eb1cd0ece6432ccdb
264 Nc3a8de01b7834f809284490cf9ac48dc rdf:first sg:person.01153663723.53
265 rdf:rest N0e6c65393d144ff9a6eba66cd19698fd
266 Nc6483fc71e184afe955f2f3a0debf844 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
267 schema:name Risk
268 rdf:type schema:DefinedTerm
269 Nc8a9c5dbde834ddc8c7b26186dcb36a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
270 schema:name Middle Aged
271 rdf:type schema:DefinedTerm
272 Ncd6909f1eb5d4e90b1b3e61d468dba78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
273 schema:name Creatinine
274 rdf:type schema:DefinedTerm
275 Nd0ea595630be49e7b3836351d56319a8 rdf:first sg:person.01037616506.85
276 rdf:rest N43bcc75b48b141e2ae0799610727b0c6
277 Nd2af1c72fe384d928b7b671469eb4466 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
278 schema:name Chelation Therapy
279 rdf:type schema:DefinedTerm
280 Nd34461914c9b454eaaf6ae3b4507673c rdf:first sg:person.01273447501.34
281 rdf:rest N68323cdc5e39466bbb6acda240d4740c
282 Nd4b9a438194f482e832d977c78f8716a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
283 schema:name Aged, 80 and over
284 rdf:type schema:DefinedTerm
285 Ne7fd4c94f18c47fc888606d35e94d897 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
286 schema:name Benzoates
287 rdf:type schema:DefinedTerm
288 Nf05c77eda2a74ce18df1cad3c98e93d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
289 schema:name Iron
290 rdf:type schema:DefinedTerm
291 Nfabbc922cb0f45e880fddc47591d9c50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
292 schema:name Deferasirox
293 rdf:type schema:DefinedTerm
294 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
295 schema:name Medical and Health Sciences
296 rdf:type schema:DefinedTerm
297 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
298 schema:name Clinical Sciences
299 rdf:type schema:DefinedTerm
300 sg:journal.1358129 schema:issn 0939-5555
301 1432-0584
302 schema:name Annals of Hematology
303 schema:publisher Springer Nature
304 rdf:type schema:Periodical
305 sg:person.01011222414.69 schema:affiliation grid-institutes:None
306 schema:familyName Lück
307 schema:givenName A.
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011222414.69
309 rdf:type schema:Person
310 sg:person.01037616506.85 schema:affiliation grid-institutes:grid.411778.c
311 schema:familyName Schumann
312 schema:givenName C.
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037616506.85
314 rdf:type schema:Person
315 sg:person.01116413157.95 schema:affiliation grid-institutes:grid.6363.0
316 schema:familyName Taupitz
317 schema:givenName M.
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116413157.95
319 rdf:type schema:Person
320 sg:person.01153663723.53 schema:affiliation grid-institutes:grid.7708.8
321 schema:familyName Lübbert
322 schema:givenName M.
323 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53
324 rdf:type schema:Person
325 sg:person.01164215515.10 schema:affiliation grid-institutes:grid.459950.4
326 schema:familyName Giagounidis
327 schema:givenName A.
328 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164215515.10
329 rdf:type schema:Person
330 sg:person.01236224761.06 schema:affiliation grid-institutes:grid.6582.9
331 schema:familyName Schrezenmeier
332 schema:givenName H.
333 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236224761.06
334 rdf:type schema:Person
335 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
336 schema:familyName Gattermann
337 schema:givenName N.
338 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
339 rdf:type schema:Person
340 sg:person.01354105066.45 schema:affiliation grid-institutes:grid.6582.9
341 schema:familyName Höchsmann
342 schema:givenName B.
343 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354105066.45
344 rdf:type schema:Person
345 sg:person.0603675126.07 schema:affiliation grid-institutes:grid.411778.c
346 schema:familyName Nolte
347 schema:givenName F.
348 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603675126.07
349 rdf:type schema:Person
350 sg:person.0637560050.50 schema:affiliation grid-institutes:grid.467675.1
351 schema:familyName Baier
352 schema:givenName M.
353 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637560050.50
354 rdf:type schema:Person
355 sg:person.0653772065.10 schema:affiliation grid-institutes:grid.467675.1
356 schema:familyName Junkes
357 schema:givenName A.
358 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653772065.10
359 rdf:type schema:Person
360 sg:person.0670313557.25 schema:affiliation grid-institutes:grid.412282.f
361 schema:familyName Platzbecker
362 schema:givenName U.
363 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670313557.25
364 rdf:type schema:Person
365 sg:person.0710371040.30 schema:affiliation grid-institutes:grid.411778.c
366 schema:familyName Hofmann
367 schema:givenName W. K.
368 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710371040.30
369 rdf:type schema:Person
370 sg:person.0754465332.53 schema:affiliation grid-institutes:grid.411984.1
371 schema:familyName Haase
372 schema:givenName D.
373 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754465332.53
374 rdf:type schema:Person
375 sg:person.0770220465.02 schema:affiliation grid-institutes:grid.467675.1
376 schema:familyName Leismann
377 schema:givenName O.
378 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770220465.02
379 rdf:type schema:Person
380 sg:pub.10.1007/s002280000251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050991082
381 https://doi.org/10.1007/s002280000251
382 rdf:type schema:CreativeWork
383 sg:pub.10.1007/s00277-010-1091-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003969238
384 https://doi.org/10.1007/s00277-010-1091-1
385 rdf:type schema:CreativeWork
386 sg:pub.10.1007/s00277-012-1481-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187265
387 https://doi.org/10.1007/s00277-012-1481-7
388 rdf:type schema:CreativeWork
389 grid-institutes:None schema:alternateName Onkologisch-urologische Praxis, Rostock, Germany
390 schema:name Onkologisch-urologische Praxis, Rostock, Germany
391 rdf:type schema:Organization
392 grid-institutes:grid.411327.2 schema:alternateName Abteilung für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
393 schema:name Abteilung für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
394 rdf:type schema:Organization
395 grid-institutes:grid.411778.c schema:alternateName III. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
396 schema:name III. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
397 rdf:type schema:Organization
398 grid-institutes:grid.411984.1 schema:alternateName Abteilung für Hämatologie und Onkologie, Universitätsmedizin Göttingen, Göttingen, Germany
399 schema:name Abteilung für Hämatologie und Onkologie, Universitätsmedizin Göttingen, Göttingen, Germany
400 rdf:type schema:Organization
401 grid-institutes:grid.412282.f schema:alternateName Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
402 schema:name Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
403 rdf:type schema:Organization
404 grid-institutes:grid.459950.4 schema:alternateName Medizinische Klinik II, Hämatologie und Onkologie, St. Johannes Hospital, Duisburg, Germany
405 schema:name Medizinische Klinik II, Hämatologie und Onkologie, St. Johannes Hospital, Duisburg, Germany
406 rdf:type schema:Organization
407 grid-institutes:grid.467675.1 schema:alternateName Novartis Pharma GmbH, Nürnberg, Germany
408 schema:name Novartis Pharma GmbH, Nürnberg, Germany
409 rdf:type schema:Organization
410 grid-institutes:grid.6363.0 schema:alternateName Institut für Radiologie und Klinik für Strahlenheilkunde, Charité Universitätsmedizin Berlin, Berlin, Germany
411 schema:name Institut für Radiologie und Klinik für Strahlenheilkunde, Charité Universitätsmedizin Berlin, Berlin, Germany
412 rdf:type schema:Organization
413 grid-institutes:grid.6582.9 schema:alternateName Institut für klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-Württemberg—Hessen und Universität Ulm, Ulm, Germany
414 schema:name Institut für klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-Württemberg—Hessen und Universität Ulm, Ulm, Germany
415 rdf:type schema:Organization
416 grid-institutes:grid.7708.8 schema:alternateName Abteilung für Innere Medizin I, Hämatologie und Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany
417 schema:name Abteilung für Innere Medizin I, Hämatologie und Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany
418 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...